The serum levels of MCP-1 and MIP-1 alpha two weeks after the onset of CRT were significantly higher in patients without residual lymph node metastasis than in those with residual lymph node metastasis (Supplementary Figs S3, S4). The gene discussed is CCL2; the disease is metastatic malignant neoplasm in the lymph nodes.